Airway microbiome studies challenge simplistic models of inhaled tobramycin benefit

Affiliations

Editorial

Geraint B Rogers. Thorax. 2020 Dec.

. 2020 Dec;75(12):1031-1032.

doi: 10.1136/thoraxjnl-2020-216005. Epub 2020 Nov 2.

¹ Microbiome Research, South Australian Health and Medical Research Institute, Adelaide, South Australia, Australia geraint.rogers@sahmri.com.

No abstract available

Keywords: cystic fibrosis.

Conflict of interest statement

Competing interests: None declared.

Maintenance tobramycin primarily affects untargeted bacteria in the CF sputum microbiome.
Nelson MT, Wolter DJ, Eng A, Weiss EJ, Vo AT, Brittnacher MJ, Hayden HS, Ravishankar S, Bautista G, Ratjen A, Blackledge M, McNamara S, Nay L, Majors C, Miller SI, Borenstein E, Simon RH, LiPuma JJ, Hoffman LR. Nelson MT, et al. Thorax. 2020 Sep;75(9):780-790. doi: 10.1136/thoraxjnl-2019-214187. Epub 2020 Jul 6. Thorax. 2020. PMID: 32631930 Free PMC article.
Sputum microbiota in adults with CF associates with response to inhaled tobramycin.
Heirali A, Thornton C, Acosta N, Somayaji R, Laforest Lapointe I, Storey D, Rabin H, Waddell B, Rossi L, Arrieta MC, Surette M, Parkins MD. Heirali A, et al. Thorax. 2020 Dec;75(12):1058-1064. doi: 10.1136/thoraxjnl-2019-214191. Epub 2020 Nov 2. Thorax. 2020. PMID: 33139451